# Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

> **NCT03457896** · PHASE2 · UNKNOWN · sponsor: **NSABP Foundation Inc** · enrollment: 35 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Cetuximab
- **DRUG:** Neratinib
- **DIAGNOSTIC_TEST:** Guardant360 Diagnostic Test

## Key facts

- **NCT ID:** NCT03457896
- **Lead sponsor:** NSABP Foundation Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-18
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03457896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03457896, "Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03457896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*